NASDAQ:MDGL
Madrigal Pharmaceuticals, Inc. Stock News
$216.05
+5.46 (+2.59%)
At Close: May 02, 2024
Trial Results Set to Make or Break Small-Cap Pharma Stocks
04:15pm, Wednesday, 06'th Jul 2022
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati
Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis
12:50pm, Monday, 27'th Jun 2022
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new deta
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
01:00pm, Saturday, 25'th Jun 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepat
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
12:00pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohep
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
08:00am, Thursday, 02'nd Jun 2022
CONSHOHOCKEN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepat
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
12:00pm, Tuesday, 17'th May 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepa
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
08:00am, Tuesday, 17'th May 2022
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepati
Madrigal Pharmaceuticals, Inc. (MDGL) CEO Paul Friedman on Q1 2022 Results - Earnings Call Transcript
12:56pm, Monday, 09'th May 2022
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2022 Results Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Paul Friedman - Chairman and Chief Executive Officer Rebecca Taub - F
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
10:30am, Monday, 09'th May 2022 GlobeNewswire Inc.
Company to host conference call at 8:00 AM ET, May 9th, 2022
Madrigal: Clear Path Ahead
02:09pm, Friday, 22'nd Apr 2022
Among many non-alcoholic steatohepatitis (NASH) drug innovators, Madrigal Pharmaceuticals is poised to deliver the first medicine to the market sometime next year. By Q4 this year, the company is anti
Madrigal: NASH Data In Q4 Is The Key
12:35pm, Tuesday, 19'th Apr 2022
MDGL announced NAFLD data in January. The 2018 NASH data has some predictive value for the phase 3 NASH trial.
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
09:30pm, Wednesday, 09'th Mar 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohe
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
09:30pm, Wednesday, 09'th Mar 2022 GlobeNewswire
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022 at 8:00 AM ET.
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
04:30pm, Wednesday, 09'th Mar 2022
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepa
Madrigal Pharmaceuticals Q4 net loss widens Y/Y
02:48pm, Thursday, 24'th Feb 2022 Seeking Alpha
Madrigal Pharmaceuticals (MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The…
